Modular Medical (NASDAQ:MODD – Get Free Report) and Anika Therapeutics (NASDAQ:ANIK – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.
Institutional and Insider Ownership
27.5% of Modular Medical shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 32.3% of Modular Medical shares are owned by company insiders. Comparatively, 7.9% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Modular Medical has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Modular Medical | N/A | N/A | -$17.47 million | ($0.68) | -3.28 |
| Anika Therapeutics | $164.17 million | 1.54 | -$82.67 million | ($6.65) | -2.57 |
Modular Medical has higher earnings, but lower revenue than Anika Therapeutics. Modular Medical is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Modular Medical and Anika Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Modular Medical | N/A | -228.12% | -178.09% |
| Anika Therapeutics | -59.40% | -2.22% | -1.75% |
Analyst Recommendations
This is a summary of recent recommendations for Modular Medical and Anika Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Modular Medical | 0 | 0 | 1 | 0 | 3.00 |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Modular Medical currently has a consensus target price of $5.00, suggesting a potential upside of 124.22%. Anika Therapeutics has a consensus target price of $24.50, suggesting a potential upside of 43.53%. Given Modular Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Modular Medical is more favorable than Anika Therapeutics.
About Modular Medical
Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.
About Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Modular Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Modular Medical and related companies with MarketBeat.com's FREE daily email newsletter.
